About LIVZON PHARMA Company

The company was founded in January 1985, with a registered capital of 719 million yuan. As of 2017, the company had total assets of 16 billion yuan, annual operating income of 8.53 billion yuan, deducting non-net profit of 820 million yuan, and R&D investment of 575 million yuan. In 1993, Lizhu's A and B shares were listed one after another; at the beginning of the 2014 new year, the company completed the conversion of B shares to H shares, making it one of the few A+H share pharmaceutical listed companies in the capital market. The company's main business is R&D, production and sales of pharmaceutical products. The main products include iLiriam (eprazole enteric tablets and eprazole sodium for injection), Ributerol (potassium bismuth citrate) series products, liberol (labeprazole sodium enteric capsules), vitamin triplets (potassium bismuth citrate tablets/tinidazole tablets/clarithromycin tablets), Bei (injectable leuprorelin acetate microspheres), lisenbao (urethromycin for injection), levodexin (ureconazole for injection), rifocon (progesterone for injection), rifocon (voriconazole for injection), rifolacin (progesterone for injection), rifocon (voriconazole for injection), rifolacin (progesterone for injection), rifocon (voriconazole for injection), rifukon (voriconazole for injection), rifolacin (progesterone for injection), rifolacin (voriconazole for injection), rifukon (voriconazole for injection), rifukon (voriconazole for injection), rifukon (voriconazole for injection) Pharmaceutical products such as loxamine maleate (fluvoxamine maleate tablets), clentin (piropyrone hydrochloride tablets), ginseng fuzheng injections, antiviral granules, etc.; mevastatin, A APIs and intermediates such as carbose, colistin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbehime, and ceftriaxone; novel coronavirus (2019-nCoV) IgM/IgG antibody test kit (colloidal gold method enterprise honor: Lizhu Delle won the first Grand Prize for Outstanding Contribution to Scientific and Technological Advancement in Zhuhai; Lizhu Giang Le won the Grand Prize for Outstanding Contribution to the Advancement of Science and Technology in Zhuhai; Lizhu Xile won the Grand Prize for Outstanding Contribution to Advancing Scientific and Technological Progress by Zhuhai; Lizhu Ziluo Injection won the Grand Prize for Outstanding Contribution to Advancing Science and Technology; Participating in Fuzheng Fuqifu Injection It won the first prize of the 2006 Science and Technology Award of the Chinese Society of Integrated Traditional Chinese and Western Medicine, etc.